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Background. The family of ubiquitin-like molecules (UbLs) comprises several members, each of which has sequence,
structural, or functional similarity to ubiquitin. ISG15 is a homolog of ubiquitin in vertebrates and is strongly upregulated
following induction by type I interferon. ISG15 can be covalently attached to proteins, analogous to ubiquitination and with
actual support of ubiquitin conjugating factors. Specific proteases are able to reverse modification with ubiquitin or UbLs by
hydrolyzing the covalent bond between their C-termini and substrate proteins. The tail regions of ubiquitin and ISG15 are
identical and we therefore hypothesized that promiscuous deubiquitinating proteases (DUBs) might exist, capable of
recognizing both ubiquitin and ISG15. Results. We have cloned and expressed 22 human DUBs, representing the major clades
of the USP protease family. Utilizing suicide inhibitors based on ubiquitin and ISG15, we have identified USP2, USP5 (IsoT1),
USP13 (IsoT3), and USP14 as ISG15-reactive proteases, in addition to the bona fide ISG15-specific protease USP18 (UBP43).
USP14 is a proteasome-associated DUB, and its ISG15 isopeptidase activity increases when complexed with the proteasome.
Conclusions. By evolutionary standards, ISG15 is a newcomer among the UbLs and it apparently not only utilizes the
conjugating but also the deconjugating machinery of its more established relative ubiquitin. Functional overlap between these
two posttranslational modifiers might therefore be more extensive than previously appreciated and explain the rather
innocuous phenotype of ISG15 null mice.
Citation: Catic A, Fiebiger E, Korbel GA, Blom D, Galardy PJ, et al (2007) Screen for ISG15-crossreactive Deubiquitinases. PLoS ONE 2(7): e679.
doi:10.1371/journal.pone.0000679
INTRODUCTION
Posttranslational modification by ubiquitin regulates processes
such as proteasomal degradation, intracellular trafficking, and
transcription. Ubiquitin is attached to substrates in covalent
isopeptide linkage or as an N-terminal fusion [1–3]. Ubiquitina-
tion, however, is reversible: the ubiquitin moiety can be released
from substrates through the action of deubiquitinating proteases,
which may rescue ubiquitinated substrates from their degradative
fate [4]. In contrast, proteasome-associated DUBs enhance the
rate of proteasomal degradation by removing bulky poly-ubiquitin
chains from substrate proteins prior to proteolysis. Such DUBs
enhance the processivity of the proteasome toward target proteins,
and also recycle ubiquitin, a modifier that itself turns over slowly
[5,6]. DUBs are furthermore required to hydrolyze the ubiquitin
precursor and generate the active ubiquitin monomer. Inspection
of mammalian genomes shows the presence of more than 100
genes that encode putative DUBs, consistent with their specific
and diverse regulatory functions. Ubiquitin-specific proteases
(USPs) are the dominant family among DUBs [7].
Ubiquitin-like molecules show sequence and structural similar-
ity to ubiquitin. Unlike ubiquitination, modification by UbLs
usually does not target proteins for destruction by the proteasome.
A notable exception may be FAT10, a modifier that serves as
a ubiquitin-independent signal for proteasomal degradation [8].
The conjugation of UbLs to target proteins follows reaction
pathways similar to those involved in ubiquitination [9]. The
enzymes that attach or cleave UbLs are generally distinct from the
ligases or proteases of the ubiquitin pathway.
A closely related homolog of ubiquitin in vertebrates is the UbL
polypeptide ISG15, an interferon-inducible gene product that is
strongly upregulated following viral or bacterial infection [10].
However, the molecular and regulatory consequences of ISGyla-
tion remain unknown [11]. ISG15 consists of two ubiquitin
domains in a tandem arrangement, similar to FAT10. Unlike
other members of the UbL family, ISG15 co-opts at least one of
ubiquitin’s conjugating enzymes, Ubc8 [12,13] and the ubiquitin
ligase Herc5 [14–17]. USP18 constitutes the only presently
appreciated isopeptidase specific for ISG15, and its absence has
profound effects on innate immunity, leading to increased
resistance to certain viral infections [18,19]. Notably, these effects
appear not to be contingent upon proteolytic activity of USP18
[20,21]. Apart from USP18, additional proteases for ISG15 must
exist, since the ISG15 precursor protein is cleaved properly in
USP18 knockout mice [19].
The C-terminal six amino acids of ubiquitin and ISG15 are
identical. This tail region is required for specific recognition of
ubiquitin by conjugating enzymes, and also for recognition of
ubiquitin adducts by isopeptidases [22,23]. The overlap in
conjugation between ubiquitin and ISG15, as well as their C-
terminal similarity, imply the existence of promiscuous DUBs,
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proteins. Here, we report on the identification of new ISG15-
specific proteases measured by reactivity toward active-site
directed probes and isopeptide-linked substrates [24–26].
RESULTS
Activity-based profiling of DUBs
Figure 1 shows a consensus phylogram based on the alignment of
catalytic core sequences of DUBs, including the majority of known
human USP homologs. In this tree, the ISG15-protease USP18
clusters close to USP5 (IsoT1) and its isoform USP13 (IsoT3).
Previous work had identified USP5 as a protease with affinity for
both ubiquitin [27] and ISG15, as shown by its reaction with an
electrophilic ISG15 derivative, ISG15-vinyl sulfone (ISG15VS)
[28]. To probe for additional ISG15-reactive proteases, we have
cloned and expressed a total of 22 human DUB homologs from
different clades of this phylogram (indicated with arrows), 17 of
which reacted with a ubiquitin-based probe and/or an ISG15-
based probe (see below). The screen was based on in vitro tran-
scription and translation (IVT) of cloned cDNAs, which affords
a rapid method to generate radiochemically pure proteins. This
technique allows the generation of DUBs that cannot be readily
expressed in bacterial systems, or that are sequestered in sub-
cellular compartments or in multimolecular complexes when
expressed in cell lines. To profile for DUB specificity, we used
recombinantly expressed ubiquitin, SUMO1 and ISG15, and
installed an electrophilic trap at their C-terminus to obtain the
active-site probes ubiquitin-vinylmethyl ester (UbVME), SU-
MO1VME and ISG15VS, respectively [28]. DUBs generated by
IVT were incubated with each of these three probes (Figure 2),
followed by direct analysis of the reaction mixture by SDS-PAGE.
We have determined by X-ray crystallography that probes of this
type form a covalent adduct with the catalytic cysteine residue of
active DUBs to yield a thioether-linked adduct between enzyme
and probe [26]. When unmodified IVT products are run adjacent
to samples incubated with these activity-based probes, the adduct
is readily detected through a shift in apparent molecular mass.
USP2, USP5, USP13 and USP14 reacted with ISG15VS
(Figure 2B, C, D, E).
The following observations confirm the validity of our assay.
First, the bona fide ISG15-isopeptidase USP18 displayed reactivity
only towards ISG15VS (Figure 2A), whereas most of the DUBs
reacted only with UbVME. An example is shown with CGI-77
(Figure 1, 2F), a previously uncharacterized Otubain-homolog.
Second, as a negative control, the SUMO protease SENP2 formed
an adduct exclusively with SUMO1VME (Figure 2G). We found
no evidence for any of the DUBs evaluated here to display
reactivity toward the SUMO1 probe (not shown). The presence of
the reactive group alone is clearly not sufficient for binding to the
active-site cysteine of a protease and specificity of a DUB thus
depends on the peptide moiety of the probe, containing either
ubiquitin, SUMO1 or ISG15. Lastly, all covalent modifications of
DUBs by active-site directed probes were blocked by pretreatment
of the translated polypeptides with the sulfhydryl alkylating agent
N-ethylmaleimide (NEM) (Figure 2), confirming the cysteine-
dependency of adduct formation.
Characterization of the abnormal size shift in
SDS-PAGE
In accordance with previous results [28], we observed a non-linear
decrease in electrophoretic mobility of the ISG15VS adducts. The
ISG15 probe has a mass of 17.4 kDa, whereas the size increase
observed for each of the DUBs investigated here is in the order of
25–110 kDa, when bound to ISG15VS. The correlation between
the abnormal shift and the initial mass of the unmodified DUB
suggests that the decrease in gel mobility is based on steric
properties of the branched adduct, and is not caused by covalent
modification of a single DUB by multiple ISG15VS molecules. In
fact, in our sample set, the observed size increase of the ISG15VS-
DUB adducts based on SDS-PAGE very closely matched
a logarithmic equation (Figure 3A and see Methods). To further
verify that DUBs are modified by only a single ISG15VS probe
per molecule, we replaced the catalytic cysteine at position 114 in
USP14 with a serine residue. As expected, this mutation abolished
all labeling (Figure 3B). Our assay was conducted in IVT lysate
and the size increase of the ISG15VS adduct could potentially
reflect modification of USP14 by additional factors. However,
even USP14 that was recombinantly expressed in bacteria and
.95% pure showed the same abnormal electrophoretic mobility
for its ISG15VS adduct (Figure 3C). Mass spectrometry confirmed
the monovalent modification of purified USP14 by ISG15VS and
excluded covalent binding of additional factors to the complex
(Figure 3D). Collectively, these experiments establish that the
observed shift in apparent molecular mass of the ISG15VS-DUB
adducts is solely a consequence of its unusual electrophoretic
behavior. It also underscores the uncertainties in estimating the
degree of modification of a target protein with UbLs by SDS-
PAGE alone.
USP14 reacts more efficiently with ISG15VS in its
proteasome-associated form
USP14 and its yeast counterpart Ubp6 show significantly higher
activity when bound to the 26S proteasome [29]. This activity may
in fact be strictly dependent on association with the proteasome, as
shown for Ubp6 [30]. As further evidence for a physiological role
of the interaction of USP14 with ISG15, we investigated whether
the allosteric activation of USP14 also influences its reactivity
toward ISG15VS. We examined labeling of USP14 with the
ubiquitin- and the ISG15-based probes as a function of the
concentration of added purified proteasomes. As a negative
control, we evaluated USP5, a DUB that is not a known
interaction partner of the 26S complex in vivo. As anticipated,
the inclusion of purified proteasomes had no effect on the
ISG15VS- or UbVME-reactivity of USP5 (Figure 4B). In contrast,
we observed a dose-dependent increase in ISG15VS adduct
formation of USP14 with increasing proteasome concentration,
indicating enhanced activity of this DUB. The effect was similar in
magnitude to that seen for the ubiquitin probe (Figure 4A, C).
USP14 is an isopeptidase only in association with
the proteasome
While recombinant USP14 in its purified form bound to
electrophilic probes (Figure 3C), we did not detect robust
hydrolytic activity against ubiquitin-AMC or against ubiquitin-
or ISG15-linked isopeptide fusion proteins (data not shown).
However, using sequential ultracentrifugation to obtain a cytosolic
fraction that is enriched in 26S proteasomes [29], we could show
that proteases in this fraction efficiently and specifically cleave an
ISG15-isopeptide linked substrate (Figure 5A, B). The absence of
proteolytic intermediates suggests specific cleavage of the isopep-
tide bond. In addition, the same bait peptide linked to SUMO1
was stable and not hydrolyzed, even upon prolonged incubation
for over 24 hours with the proteasome fraction. Proteolysis of the
ISG15-linked peptide substrate was inhibited by inclusion of
NEM, indicating cleavage by cysteine proteases. Analysis by
reaction with ISG15VS supports that USP14 is the only active
ISG15-specific Proteases
PLoS ONE | www.plosone.org 2 July 2007 | Issue 7 | e679Figure 1. Phylogram representation of DUBs. Indicated with arrows are DUB homologs that were cloned and expressed by in vitro transcription/
translation (IVT). Red arrows depict DUBs that bound to neither probe (UbVME, ISG15VS, or SUMO1VS), whereas black arrows indicate DUBs that
formed covalent adducts with the indicated probes. Our screen represents the first biochemical proof for protease activity of USP13 and the Otubain-
homolog CGI-77 (DUB homologs without publication record regarding biochemical function are marked with an asterisk). Otubain1 (OTU1) is an
exception in that it binds to alkylhalide- or aldehyde-based probes, but not to the Michael acceptors employed in this study (data not shown).
doi:10.1371/journal.pone.0000679.g001
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(Figure 5C). While we cannot formally exclude the possibility of
a yet undefined enzyme binding to ISG15VS, we consider this
unlikely: such a protease would have to display a mass highly
similar to that of USP14 and, furthermore, it would have to
sediment after centrifugation for 5 hours at 100,000 g. However,
only few deubiquitinating enzymes are sedimentable, none at
a level comparable to USP14 [29,31].
Activity in cell lysate and subcellular distribution of
DUBs
The wealth of USPs found in the human proteome likely reflects
substrate specificity, but potentially also complementation in terms
of expression profiles and subcellular distribution. We therefore
sought to analyze the intracellular distribution pattern of a subset
of our crossreactive DUBs, using confocal microscopy. The
analysis of a genome-wide set of C-terminal GFP fusion proteins
for yeast had shown remarkably few with altered function or
subcellular distribution (,5%), validating the choice of such C-
terminal modifications [32]. Using anti-G/YFP antibodies, we also
utilized this tag to assay for activity of DUBs in cell lysate. We
cloned and transiently expressed five USP-EYFP constructs in
293T cells: USP5, USP13, USP14, USP3, and USP36 (Figure 6A).
Lysate of USP14EYFP transfected cells was incubated with the
ubiquitin and the ISG15 probe, and assayed by anti-YFP
immunoblot analysis (Figure 6B). Whereas the USP14EYFP
construct reacted with both probes, the respective C114S mutant
Figure 2. Activity-based profiling of DUBs. IVT was used to generate DUBs for profiling activity toward ISG15VS, UbVME and SUMO1VME probes.
After incubation with the probes, samples were analyzed by SDS-PAGE, as shown for USP18 (A), USP14 (B), USP5 (C), USP13 (D), USP2 (E), and CGI-77
(F). Binding was inhibited by preincubation of the proteases with NEM. The SUMO protease SENP2 interacts specifically with SUMO1VME (G).
Molecular weight in kDa is indicated on the left.
doi:10.1371/journal.pone.0000679.g002
ISG15-specific Proteases
PLoS ONE | www.plosone.org 4 July 2007 | Issue 7 | e679Figure 3. Unexpected apparent molecular mass of ISG15VS-DUB adducts is caused by unusual behavior in SDS-PAGE. (A) Plot showing the ratio of
observed versus expected ISG15VS-DUB adduct size of USP2, USP5, USP13, USP14 and USP18 in SDS-PAGE (8%) over the size of the unmodified DUBs. (B)
Mutation of the catalytic cysteine residue to serine (C114S) in USP14 abolishes its reactivity toward UbVME and ISG15VS. When stored for longer periods at
room temperature, the probes polymerize covalently, presumably by formation of secondary amine bonds between internal lysine residues and the
reactiveMichaelacceptor at theC-terminus, thus resemblingisopeptide-linkedpolyubiquitin.Suchpolymeric probes ofUbVMElikely causedthe additional
high-molecular mass adducts observed for USP14. Note that the smallest version of these adducts (a UbVME dimer) has a maximum electrophoretic
mobility similar to that of the diubiquitin-like ISG15VS when complexed to USP14. The absence of any adducts in the C114S mutant of USP14 excludes the
possibility of multiple binding sites for the probes. (C) Purified recombinant USP14 labels with UbVME and ISG15VS and results in the same abnormal
mobility shift for ISG15VS-USP14 as seen in the IVT labeling experiments. (D) MALDI-TOF mass spectroscopic analysis of USP14 after incubation with
ISG15VS.As described above for UbVME, ISG15VS alsoengages in internal polymerization. Molecularmasses consistent withtri- andtetrameric ISG15VS are
marked in this spectrogram by the numbers in superscript.Monovalently modified USP14 results in an adduct of predicted size, indicated witha red arrow.
This complex is uniquetothe mixture containing both USP14and ISG15VS,and is absent in the mass spectra of either component alone (data not shown).
doi:10.1371/journal.pone.0000679.g003
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respect to subcellular distribution, we were particularly interested
in the expression pattern of USP5 and USP13, given that these
two isoforms displayed different specificity in UbVME and
ISG15VS labeling experiments. USP5EYFP was found throughout
the cell (Figure 6C, upper left panel), similar to USP18 [33]. In
contrast, its close relative USP13EYFP was expressed mainly in the
nucleus in a speckled pattern (Figure 6C, upper right panel).
Consistent with the in vivo interaction between USP14 and the
proteasome [5], we observed USP14EYFP predominantly in the
cytoplasm, though we also noticed fluorescence in the nucleus
(Figure 6C, lower left panel). To demonstrate that the presence of
the C-terminal YFP fusion does not interfere with the endogenous
distribution of these enzymes, we analyzed USP3EYFP (Figure 6C,
lower right panel) and USP36EYFP (Figure 6C, lower right panel).
USP3 is predicted to be a nuclear protein [34] and USP36 was
Figure 4. Reactivity of USP14 toward ISG15VS is augmented by
proteasomal association. USP14 and USP5 were generated by IVT.
Their activity toward ISG15VS and UbVME was analyzed in the presence
of increasing concentrations of purified human 26S proteasomes. (A)
Activity of USP14 toward UbVME and ISG15VS increases as a function of
the concentration of added purified 26S proteasomes (in mg/ml). (B)
The activity of USP5 remains unaffected. (C) Quantification of the
radioactive signal of covalently modified USP5 and USP14. Binding
affinity is depicted on the y-axis as percent in labeling intensity,
determined by the ratio of labeled versus unlabeled USP5 or USP14. The
ratio in the absence of exogenous proteasomes is defined as 100%.
doi:10.1371/journal.pone.0000679.g004
Figure 5. Proteasome-associated USP14 has ISG15-specific isopepti-
dase activity. (A) Scheme depicting the UbL-peptide conjugate used to
assay isopeptidase activity. The biotinylated peptide heptamer is
attached to either ISG15 or SUMO1 in isopeptide-linkage. Upon
hydrolysis of the isopeptide bond by a specific DUB, the heptamer is
released and the biotin signal lost. (B) Incubation of proteasome-
enriched fraction (‘‘5 hr pellet’’) with UbL-peptide conjugate. After
overnight incubation, the ISG15-peptide conjugate is completely
cleaved, resulting in loss of the biotin-signal (significant proteolysis
occurs already after one hour, data not shown). This activity is sensitive
to NEM. Hydrolysis is not observed for the SUMO1-peptide conjugate.
(C) Anti-HA immunoblot of HA-ISG15VS treated subcellular fractions.
Based on previous identification [28] and on electrophoretic mobility,
USP5 is the dominant ISG15-reactive DUB in the five-hour supernatant,
which is enriched for uncomplexed proteins of light and moderate size
(red asterisk). The five-hour pellet represents heavy cytosolic complexes,
in particular the 26S proteasome, and contains USP14 as the only ISG15-
reactive DUB (blue asterisk).
doi:10.1371/journal.pone.0000679.g005
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in the expected subcellular compartment. Combined, these results
indicate that ISG15-specific proteases are expressed throughout
the cell – a feature also proposed for DUBs. This observation
supports the notion that unlike SUMOylation, which is believed to
mostly occur in the nucleus [36], ISG15-modification affects many
cellular compartments.
DISCUSSION
Our data show the existence of multiple ISG15-reactive DUBs,
a finding that further strengthens the similarities between ubiquitin
and ISG15. USP2 is a highly active protease [37] and it represents
one of only few mammalian DUBs with a known target. USP2
exhibits oncogenic potential in prostate cancer by stabilizing its
Figure 6. In vivo probe-binding studies and analysis of subcellular DUB localization. (A) Schemes of the EYFP fusion proteins: UCH-like Zinc Finger
Motif (red), proteolytic UCH domain (blue, with the putative active-site cysteine depicted in yellow), ubiquitin-binding UBA-domain (light blue),
ubiquitin-like domain (green), putative nuclear localization sequence (pink), EYFP fusion protein (yellow box). (B) In vivo binding of ubiquitin and
ISG15 probes. Lysates obtained from 293T cells transfected with USP14EYFP or USP14C114S-EYFP were reacted with UbVME or ISG15VS and compared to
untreated aliquots in an anti-YFP immunoblot. USP14EYFP but not USP14C114S-EYFP reacts with the probes. (C) Subcellular localization of DUBs analyzed
via the distribution of C-terminal EYFP fusions. 24 hours post-transfection, 293T cells were fixed with paraformaldehyde and analyzed by confocal
fluorescence microscopy. USP5EYFP can be found throughout the cell (upper left). USP13EYFP is expressed mainly within the nucleus, in a speckled
pattern (upper right panel). USP14EYFP is detected predominantly in the cytoplasm, with lower levels in the nucleus (lower left panel). USP3EYFP and
USP36EYFP (lower right panel) are detected in the nucleus and nucleolus, respectively.
doi:10.1371/journal.pone.0000679.g006
ISG15-specific Proteases
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been identified as a target of ISG15 modification [39].
Furthermore, USP2 has been implicated in the regulation of the
p53 pathway [40]. The recently solved structures of USP2 and
USP14 [41,42] show that both proteases accommodate the
ubiquitin molecule in a shallow pan-like protrusion. Based on
the orientation of the ubiquitin protein in both structures, ISG15
easily fits into the catalytic domain of USP2, USP14, and USP5
(data not shown) without apparent steric clashes (Figure 7) [23,43].
Stimulation by interferons alters the composition of the
proteolytic proteasome core [44], tailoring its activity toward
generation of peptide-MHC complexes for inspection by the
immune system. Interferon treatment also results in enhanced
modification of proteins by ISG15 - a factor that evolved in the
vertebrate lineage, and whose origin thus coincides with that of the
adaptive immune system. Interestingly, inhibition of the proteasome
leads to rampant accumulation of ISG15-modified substrates [45].
While nothing is known about the molecular functions of ISG15, its
structural relative FAT10 is a modifier that destines proteins for
degradation by the proteasome [8]. We now have demonstrated that
USP14 exhibits proteasome-associated isopeptidase activity toward
ISG15. Could therefore ISG15 be a (co-)modifier of proteins
destined for proteasomal degradation? We have found no evidence
that USP14 markedly changes the amount of ISG15-modified
substrates in cells (data not shown). However, USP14 is not a vital
protease [30,46] and its low catalytic turnover does not affect overall
ubiquitin conjugation either [47]. A recent study suggests that
USP14 might have a more complex role, by inhibiting the
proteasome in addition to acting as a deubiquitinase [48].
The close sequence relationship between USP5 and USP13
(61.4% identity, 26.9% similarity) is contrasted by the functional
differences and localization of these two proteases. These enzymes
provide a unique opportunity to investigate the structural features
that may contribute to ubiquitin versus ubiquitin-like specificity. A
characteristic of USP5 and USP13 is the tandem occurrence of
a UBA domain, which has been implicated in the binding of
ubiquitin [49]. Our results raise the possibility that UBA domains
in general interact not only with ubiquitin, but also with ISG15.
Alternatively, ISG15 with its multiple lysines could act as
a ubiquitination anchor, and USP5 may be a protease responsible
for depolymerization of such chains [50,51]. Moreover, the C-
terminal hydrolase that processes the ISG15 precursor has not
been identified yet, and any of the novel ISG15-specific proteases
described here are potential candidates.
Conclusion
The ubiquitin gene is prone to duplications and insertions, leading
to the formation of new fusion proteins [52,53]. ISG15 likely
emerged approximately 400–600 million years ago, when
a nucleotide stretch from the polyubiquitin precursor gene,
encoding a ubiquitin-dimer, was accidentally inserted in an area
of the genome that was or that came under control of an interferon
promoter. From an agnostic point of view, one could argue that
ISG15 simply has no relevant function. The moderate or absent
phenotype of the ISG15 knockout in mice [11], the fact that
ISG15 has not (yet) established its very own family of conjugating
and deconjugating enzymes, and ISG15’s relatively low degree of
conservation between species would all support this view. Yet,
ISG15’s massive expression upon interferon challenge [54] likely
reflects a role in anti-microbial or anti-viral defense [55–59]. And
adaptation to the specific needs of host immunity often demands
polymorphism. As a result, some genes most critical to the immune
response are paradoxically least conserved. For example, cytokines
and cytokine receptors substantially differ between species [60]
and it is interesting to note that ISG15 and ubiquitin were initially
reported to be cytokines [61,62]. Similar observations were made
Figure 7. Structures of USP2 and USP14, modeled with ubiquitin and ISG15. Both USP2 and USP14 accommodate ubiquitin (green) in a shallow
groove, measuring approximately 25–30 A ˚ in diameter (view from top shown in the upper panels, view from front shown in the lower panels). Based
on these complexes, the C-terminal domain of ISG15 (red) can be modeled into the groove to replace ubiquitin. The N-terminal domain of ISG15 is
not involved in the hydrolysis reaction, and is located outside of the catalytic core domain of both proteases. The N-termini of USP2 and USP14 are
lacking in these representations and extend to the right side of the structure models.
doi:10.1371/journal.pone.0000679.g007
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MNSFb) [63,64]. If true, how do these factors gain access to the
secretory pathway? It may pay to approach ISG15 from a less
conventional perspective and from this vantage point, we might
uncover new functions of ubiquitin as well.
METHODS
DNA constructs
USP2 and USP18 cDNAs were cloned from a human kidney cDNA
library (BioChain Institute, Inc.). The cDNAs encoding the other
human DUBs were obtained from ATCC. All cDNAs encoding full-
length DUBs were subcloned into pcDNA3.1. Point mutations were
generated with the Stratagene ‘‘Quik Change II’’ kit. The Genbank
Identification numbers of the cloned constructs are: USP2
(GI:21361712), USP3 (GI:10720340), USP5 (GI:4507855), USP7
(GI:4507857),USP10 (GI:24307889), USP12 (GI:32698815), USP13
(GI:4507849), USP14 (GI:4827050), USP17/DUB3 (GI:37778800),
USP18 (GI:32313610), USP22 (GI:113426698), USP24
(GI:113408685), USP25 (GI:6941888), USP35 (GI:89034166),
USP36 (GI:35250686), USP37 (GI:32698744), Bap1 (GI:4757836),
CylD (GI:14165258), CGI-77 (GI:40254879), OTU1
(GI:109148508), OTU2 (GI:12962939), UCH-L1 (GI:93279272).
Bioinformatics
The protein sequences of human DUBs were obtained from the
National Library of Medicine and the core domains were aligned
with the CLUSTALW algorithm (EBI server) [65] and manually
edited with Genedoc (http://www.psc.edu/biomed/genedoc/) by
K.B. Nicholas & HB Nicholas Jr., using the putative active-site
cysteine as an alignment anchor. The phylogram represents
a consensus tree based on 100 bootstrap iterations, calculated by
the Minimum Evolution method under default parameters [66].
In vitro transcription and translation (IVT)
IVT was performed using the ‘‘TNT-T7 Quick Reticulocyte
Lysate System’’ kit (Promega) for 30 to 45 min (0.25–1 mg DNA
per reaction). Then, aliquots of the reaction mix were treated with
RNase B (1 mg/ml, Sigma) for 10 min and incubated with the
probes as described below. SDS-PAGE followed by fluorography
was performed as described [67].
Labeling with ubiquitin and UbL electrophilic
probes
The synthesis of human ubiquitin and UbL probes has been
described [24,28]. IVT products were incubated with saturating
amounts of the individual probes (0.2–0.4 mg/10 ml IVT lysate).
Preincubation with NEM was performed for 10 min at room
temperature at a final concentration of 10 mM, after RNase B
treatment. Autoradiograms were subjected to quantification of the
optical density with NIH Image software (version 1.32j) as ratio of
labeled versus unlabeled IVT products. Purified human 26S
proteasomes for the experiments in Figure 4 were purchased from
Biomol International and inhibited with MG132 (50 mM). E. coli-
expressed human recombinant USP14 for the experiments shown
in Figure 3C and 3D was purchased from Boston Biochem. The
observed size of ISG15VS-adducts in SDS-PAGE (8%) followed
a logarithmic equation (R
2.0.99):
O~E  ½ 0:7479   ln(M){1:4332  ,
with O being the observed adduct size, E the expected adduct size,
and M the mass of the unmodified DUB (for M.25 kDa).
Synthesis of ISG15- and SUMO1-branched peptide
conjugates
To 50 mL of conjugation buffer (100 mM Tris, pH 7.4, 5 mM
MgCl2, 20 mM DTT, 40 mM ATP) was added ISG15 (Boston
Biochem, 9.4 mM final) or GST-SUMO1 (Boston Biochem,
10.4 mM final) and biotinylated peptide 7-mer (biotin-VKAKIQD-
OH, 250 mM final). The solution was mixed thoroughly and to this
was added ISG15 activating enzyme (Boston Biochem, ISG15 E1,
50 nM final) and UbcH8 (Boston Biochem, 250 nM final), or
SUMO activating enzyme (SAE1/SAE2 heterodimer, 50 nM final)
and UbcH9 (250 nM final). The solution was mixed and incubated
for 15 hours at 37uC. The reaction mixture was transferred to
a microcentrifuge membrane filter (Vivascience, 5000 Da MWCO),
diluted to 600 mL total volume with 50 mM Tris, pH 7.4 and
concentrated at 4uCt o5 0mL. This dilution/concentration pro-
cedure was repeated six times. The products were transferred to
a clean tube and diluted with 50 mM Tris, pH 7.4 to a final volume
of 100 mL. The SUMO1- and ISG15-linked biotinylated isopeptide
was detected after transfer to a PVDF membrane (Perkin Elmer)
with Streptavidin-HRP (Amersham).
Subcellular fractionation and isopeptide cleavage
assay
EL4 cells were lysed with glassbeads and the proteasome-enriched
fraction was retrieved by consecutive ultracentrifugation steps as
previously described [29]. Proteasome activity was inhibited with
MG132 (50 mM). 10 mg of fraction protein were incubated with
0.2 mg of N-terminally HA-tagged ISG15VS in a total volume of
10 ml for two hours at room temperature to detect ISG15VS-
reactive proteases by anti-HA immunoblotting. The cleavage assay
for ISG15- or SUMO1-branched peptides was performed at 37uC
using 20 mg of total protein from the proteasome-enriched fraction
and 5 ml of branched peptides in a total volume of 10 ml. HA-
ISG15VS treated subcellular fractions were analyzed with a mono-
clonal anti-HA antibody (12CA5). Immunoblotting was performed
as published [67].
Cell lines, transient transfections and anti-YFP
immunoblotting
293T cells were maintained in DME medium as described [67].
Various constructs were expressed by transient transfection, using
a liposome-mediated transfection protocol (5–10 mg of DNA/
20 ml of Lipofectamine-2000 per 10 cm dish; Invitrogen) as
described [67]. Cells were analyzed between 24 and 48 h after
transfection. C-terminal EYFP fusion proteins of DUBs were
generated by subcloning from pcDNA3.1 into pEGFP-N1
(Clontech). NP40 lysates of USP14EYFP and USP14C114S-EYFP
transfected 293T cells were prepared and incubated with active-
site probes as described [24]. Due to the high similarity with GFP,
EYFP fusion proteins can be detected with a polyclonal anti-GFP
rabbit serum [68]. Immunoblotting was performed as published
[67].
Confocal microscopy
Immunofluorescence experiments were performed as described
[67] with minor modifications. Cells were allowed to attach to
slides overnight. After fixation with 3.7% paraformaldehyde for
20 min at room temperature, subcellular localization of EYFP
fusion proteins was analyzed with a Perkin Elmer spinning disk
confocal microscope Ultraview RS system. The microscope used
was a Nikon TE2000-U inverted unit with a Nikon 10061.4NA
DIC lens. The imaging medium was Nikon type A immersion oil.
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The structures of USP2 and USP14 in complex with ubiquitin and
the structure of ISG15 were obtained from the PDB website
(2HD5, 2AYO, 1Z2M) and ISG15 was manually modeled onto
USP2 and USP14 with the SPDB-Viewer [69].
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